Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. reported second quarter 2026 results and pipeline updates. The company is advancing CNTY-813, an iPSC-derived cell therapy for type 1 diabetes, having held a pre-IND meeting with the FDA that yielded alignment on its nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design. Phase 1 manufacturing has been established with consistent product quality, and an IND filing for CNTY-813 remains on track for the fourth quarter of 2026. CNTY-308 is planned to enter the clinic in 2026.
For the quarter ended June 30, 2026, Century reported no collaboration revenue, compared with $109.2 million in collaboration revenue in the first half of 2025. The company recorded a net loss of $34.6 million for the quarter and $56.2 million for the first half of 2026, versus net income of $44.0 million in the first half of 2025. Results include an $11.1 million loss on lease component termination. Research and development expenses declined to $19.6 million from $26.9 million in the prior-year quarter, and general and administrative expenses fell to $5.8 million from $7.8 million. As of June 30, 2026, cash and cash equivalents were $49.6 million, with short-term investments of $70.1 million and long-term investments of $77.5 million.
Century Therapeutics reported a larger net loss as collaboration revenue fell away but liquidity strengthened. For the quarter ended June 30, 2026, net loss was $34.6 million (six‑month loss $56.2 million) versus six‑month net income of $44.0 million a year earlier, when $109.2 million of Bristol‑Myers Squibb collaboration revenue was recognized.
Total assets were $287.0 million, including cash, cash equivalents and investments of $197.2 million. A January 2026 private placement raised about $126.4 million, increasing shares outstanding to 180.5 million. Management expects existing cash resources to fund operations into the first quarter of 2029.
Research and development and general and administrative expenses declined year over year, but results included an $11.1 million loss on a Philadelphia lease component termination. The company derecognized $3.8 million of contingent consideration after milestones expired and continues IND‑enabling work on lead programs CNTY‑813 and CNTY‑308.
Century Therapeutics, Inc. senior vice president of Finance & Operations Douglas Carr reported selling 275 shares of common stock on August 3, 2026 at $1.977 per share. According to the footnote, these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units, and were not sold at his discretion. Following the sale, Carr directly held 504819 shares of common stock.
Century Therapeutics, Inc. updated the employment terms for its Chief Scientific Officer, Chad Cowan, Ph.D., through an Amended and Restated Employment Agreement. Under this new arrangement, he will continue serving as Chief Scientific Officer on a part-time basis with a reduced annual salary of $296,150.
Dr. Cowan will remain eligible for an annual performance-based target bonus, calculated on a pro-rated basis to reflect his part-time role. If his employment ends through termination by the company or his resignation, he will receive all accrued and unpaid base salary through his final date of employment.
Century Therapeutics, Inc. executive Gregory Russotti reported an automatic sale of shares to cover taxes on vested stock awards. On June 12, 2026, 2,584 shares of common stock were sold in open-market transactions at an average price of $2.232 per share to satisfy tax withholding obligations tied to restricted stock unit vesting. The filing explains these sales were automatic and not at Russotti’s discretion. After the sale, he directly held 512,319 common shares and indirectly held 92,773 shares through the Gregory Russotti 2021 Family Trust.
Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of common stock tied to tax withholding. On June 12, 2026, he sold 1,654 shares at $2.232 per share in an open-market transaction to cover taxes from restricted stock unit vesting.
These sales were executed automatically and not at his discretion, according to the disclosure. After the transaction, Carr still directly owns 505,094 shares of Century Therapeutics common stock, indicating he retains a substantial equity position in the company.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 13,849 shares of Common Stock at $2.24 per share to satisfy tax withholding obligations. This was not an open-market sale, and Pfeiffenberger continues to hold 3,665,474 shares of Common Stock directly after the transaction.
Century Therapeutics, Inc. Chief Scientific Officer Chad Cowan reported routine share activity related to equity compensation. On June 11, 2026, 358 shares of common stock were withheld at $2.24 per share to cover tax obligations upon the vesting of restricted stock units, which is not an open-market sale. After this tax-withholding disposition, Cowan directly holds 1,175,322 common shares. A separate entry reports 10,697 common shares held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except to any pecuniary interest.
Century Therapeutics director Alessandro Riva received a grant of stock options as compensation. The Form 4 shows an award of 74,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $2.24 per share.
The options expire on June 11, 2036 and vest on the earlier of June 11, 2027 or the next annual meeting of stockholders, in each case only if Riva continues in service through the vesting date. Following this grant, he holds 74,000 options directly.
Century Therapeutics director Daphne Quimi received a grant of stock options for 74,000 shares of Common Stock. The options have an exercise price of $2.24 per share, expire on June 11, 2036, and vest on the earlier of June 11, 2027, or the next annual stockholder meeting, subject to continued service. Following this grant, Quimi holds 74,000 stock options directly.